Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34 Filing Table of Contents
Document/ExhibitDescriptionPagesSize
1: 10-K Annual Report HTML 1.67M
2: EX-4.12 Instrument Defining the Rights of Security Holders HTML 53K
4: EX-10.17 Material Contract HTML 46K
5: EX-10.19 Material Contract HTML 44K
3: EX-10.2 Material Contract HTML 76K
6: EX-10.21 Material Contract HTML 45K
7: EX-10.22 Material Contract HTML 86K
8: EX-10.23 Material Contract HTML 67K
9: EX-10.32 Material Contract HTML 410K
10: EX-10.35 Material Contract HTML 137K
11: EX-10.36 Material Contract HTML 41K
12: EX-10.37 Material Contract HTML 41K
13: EX-10.38 Material Contract HTML 171K
14: EX-10.39 Material Contract HTML 39K
15: EX-21.1 Subsidiaries List HTML 32K
16: EX-23.1 Consent of Experts or Counsel HTML 32K
17: EX-31.1 Certification -- §302 - SOA'02 HTML 38K
18: EX-31.2 Certification -- §302 - SOA'02 HTML 38K
19: EX-32.1 Certification -- §906 - SOA'02 HTML 35K
20: EX-32.2 Certification -- §906 - SOA'02 HTML 34K
29: R1 Cover HTML 99K
91: R2 Consolidated Balance Sheets HTML 118K
99: R3 Consolidated Balance Sheets (Parenthetical) HTML 59K
69: R4 Consolidated Statements of Operations and HTML 91K
Comprehensive Loss
32: R5 Consolidated Statements of Convertible Preferred HTML 130K
Stock, Redeemable Common Stock and Stockholders'
Equity (Deficit)
94: R6 Consolidated Statements of Convertible Preferred HTML 39K
Stock, Redeemable Common Stock and Stockholders'
Equity (Deficit) (Parenthetical)
102: R7 Consolidated Statements of Cash Flows HTML 135K
66: R8 Nature of the Business and Basis of Presentation HTML 53K
33: R9 Summary of Significant Accounting Policies HTML 166K
111: R10 Merger Accounting HTML 68K
81: R11 License, Collaboration, and Funding Agreements HTML 64K
46: R12 Fair Value of Financial Assets and Liabilities HTML 103K
61: R13 Property and Equipment, Net HTML 50K
112: R14 Accrued Expenses HTML 44K
82: R15 Long-Term Debt HTML 77K
47: R16 Leases HTML 77K
62: R17 Commitment and Contingencies HTML 42K
113: R18 Preferred and Common Stock Warrants HTML 160K
80: R19 Common Stock, Redeemable Common Stock and HTML 69K
Convertible Preferred Stock (converted to Common
Stock)
27: R20 Stock-Based Compensation HTML 107K
63: R21 Income Taxes HTML 136K
95: R22 Net Loss per Share HTML 74K
85: R23 Loss on Transfer of Nonfinancial Assets HTML 37K
28: R24 Summary of Significant Accounting Policies HTML 200K
(Policies)
64: R25 Summary of Significant Accounting Policies HTML 72K
(Tables)
96: R26 Merger Accounting (Tables) HTML 66K
86: R27 Fair Value of Financial Assets and Liabilities HTML 96K
(Tables)
26: R28 Property and Equipment, Net (Tables) HTML 50K
65: R29 Accrued Expenses (Tables) HTML 44K
60: R30 Long-Term Debt (Tables) HTML 56K
44: R31 Leases (Tables) HTML 68K
84: R32 Preferred and Common Stock Warrants (Tables) HTML 159K
115: R33 Common Stock, Redeemable Common Stock and HTML 59K
Convertible Preferred Stock (converted to Common
Stock) (Tables)
58: R34 Stock-Based Compensation (Tables) HTML 101K
43: R35 Income Taxes (Tables) HTML 136K
83: R36 Net Loss per Share (Tables) HTML 74K
114: R37 Nature of the Business and Basis of Presentation HTML 61K
(Details)
55: R38 Summary of Significant Accounting Policies - HTML 55K
Schedule of Restricted Cash (Details)
45: R39 Summary of Significant Accounting Policies - HTML 44K
Schedule of Cash, Cash Equivalents and Restricted
Cash (Details)
72: R40 Summary of Significant Accounting Policies - HTML 47K
Schedule of Property, Plant and Equipment
(Details)
35: R41 Summary of Significant Policies - Additional HTML 54K
Information (Details)
89: R42 Merger Accounting - Additional Information HTML 64K
(Details)
98: R43 Merger Accounting - Preliminary Purchase Price HTML 50K
Paid (Details)
71: R44 Merger Accounting - Summary of Purchase Price HTML 61K
Allocation (Details)
34: R45 Merger Accounting - Supplemental Pro Forma HTML 37K
Information (Details)
88: R46 License, Collaboration, and Funding Agreements - HTML 56K
Genzyme Agreement (Details)
97: R47 License, Collaboration, and Funding Agreements - HTML 43K
Georgetown Agreement (Details)
70: R48 License, Collaboration, and Funding Agreements - HTML 38K
Beth Israel Deaconess Medical Center Agreements
(Details)
36: R49 License, Collaboration, and Funding Agreements - HTML 46K
Research and Development Incentive Program
(Details)
41: R50 Fair Value of Financial Assets and Liabilities - HTML 57K
Measured on a Recurring Basis (Details)
52: R51 Fair Value of Financial Assets and Liabilities - HTML 54K
Narrative (Details)
104: R52 Fair Value of Financial Assets and Liabilities HTML 53K
-Aggregate Fair Value of Warrant and Derivative
Liabilities (Details)
73: R53 Property and Equipment, Net (Details) HTML 57K
42: R54 Accrued Expenses (Details) HTML 46K
53: R55 Long-Term Debt - Schedule of Long-Term Debt HTML 46K
(Details)
105: R56 Long-Term Debt - SVB Loan Agreement (Details) HTML 58K
74: R57 Long-Term Debt - Hercules Loan Agreements HTML 73K
(Details)
40: R58 Long-Term Debt - 2019 Amended and Restated Loan HTML 104K
Agreement (Details)
54: R59 Long-Term Debt - FFG Loan Agreements (Details) HTML 58K
100: R60 Long-Term Debt - Future Principal Payments HTML 47K
(Details)
92: R61 Leases (Details) HTML 84K
30: R62 Leases - Schedule of Components of Lease Expense HTML 53K
(Details)
67: R63 Leases - Schedule of Maturities of Lease HTML 47K
Liabilities (Detail)
101: R64 Leases - Schedule of Lease Liability Not Yet HTML 51K
Commenced (Details)
93: R65 Leases - Future Minimum Lease Payments (Details) HTML 46K
31: R66 Commitment and Contingencies (Details) HTML 61K
68: R67 Preferred and Common Stock Warrants - Additional HTML 60K
Information (Details)
103: R68 Preferred and Common Stock Warrants - Schedule of HTML 50K
Outstanding Warrants (Detail)
90: R69 Preferred and Common Stock Warrants - Summary of HTML 97K
Outstanding Warrants to Purchase Shares of Common
Stock (Details)
77: R70 Common Stock, Redeemable Common Stock and HTML 89K
Convertible Preferred Stock (converted to Common
Stock) - Additional Information (Details)
109: R71 Common Stock, Redeemable Common Stock and HTML 61K
Convertible Preferred Stock (converted to Common
Stock) - Schedule of Preferred Stock (Details)
50: R72 Stock-Based Compensation - Additional Information HTML 87K
(Details)
38: R73 Stock-Based Compensation - Stock Option Valuation HTML 44K
(Details)
76: R74 Stock-Based Compensation - Summary of Stock Option HTML 92K
Activity (Detail)
108: R75 Stock-Based Compensation - Restricted Stock Units HTML 44K
(Details)
49: R76 Stock-Based Compensation - Summary of Stock-Based HTML 41K
Compensation Expense Classification (Details)
37: R77 Income Taxes - Schedule of Income Loss Before HTML 40K
Income Taxes (Details)
79: R78 Income Taxes - Reconciliation of Effective Income HTML 63K
Tax Rate (Details)
106: R79 Income Taxes - Deferred Income Tax Asset (Details) HTML 64K
78: R80 Income Taxes - Narrative (Details) HTML 52K
110: R81 Income Taxes - Deferred Tax Valuation Allowance HTML 41K
(Details)
51: R82 Net Loss per Share - Summary of Basic and Diluted HTML 49K
Net loss per Share Attributable to Common
Stockholders (Details)
39: R83 Net Loss per Share - Additional Information HTML 47K
(Details)
75: R84 Net Loss per Share - Schedule of Anti-dilutive HTML 44K
Securities Excluded from Computation of Diluted
Net Loss per Share Attributable to Common
Stockholders (Details)
107: R85 Loss on Transfer of Nonfinancial Assets - HTML 42K
Additional Information (Details)
57: XML IDEA XML File -- Filing Summary XML 195K
87: XML XBRL Instance -- xfor-20191231_htm XML 2.86M
59: EXCEL IDEA Workbook of Financial Reports XLSX 128K
22: EX-101.CAL XBRL Calculations -- xfor-20191231_cal XML 277K
23: EX-101.DEF XBRL Definitions -- xfor-20191231_def XML 953K
24: EX-101.LAB XBRL Labels -- xfor-20191231_lab XML 2.13M
25: EX-101.PRE XBRL Presentations -- xfor-20191231_pre XML 1.37M
21: EX-101.SCH XBRL Schema -- xfor-20191231 XSD 260K
48: JSON XBRL Instance as JSON Data -- MetaLinks 421± 672K
56: ZIP XBRL Zipped Folder -- 0001628280-20-003484-xbrl Zip 1.00M
This Amendment No. 2 (the “Amendment”) is made as of February 28th, 2020 (“Effective Date”) by and between Mayne Pharma Inc. (formerly known as Metrics, Inc.), doing business as Metrics Contract Services, a North Carolina corporation, having a principal place of business at 1240 Sugg
Parkway, Greenville, NC27834 (“Metrics”) and X4 Pharmaceuticals Inc., a Delaware corporation with a business address at 955 Massachusetts Avenue, Fourth Floor, Cambridge, MA02139 (“Company”).
RECITALS
Whereas
Metrics and Company entered into that certain Master Services Agreement for the provision of pharmaceutical development services dated September 10, 2015, as amended (by Amendment No. 1) on August 25, 2017 (the “Agreement”); and
Whereas the parties desire to amend the Agreement to, among other things, renew the Term of the Agreement.
Now, therefore, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:
1.Despite
the expiration of the Term of the Agreement on September 10, 2018, the parties have continued to perform their respective obligations for Work Orders in effect in accordance with the terms and conditions of the Agreement. Therefore, in accordance with Section 13.1, the Agreement continued in full force and effect.
2.Since September 10, 2018, Company has continued to pay in full all invoices submitted by Metrics in accordance with the terms of the Agreement. For the avoidance of doubt, the parties agree that such invoices are a part of the Agreement and the terms and conditions of the Agreement have governed over such invoices since the effective date of the Agreement.
3.The Term is extended
for five (5) years to a total eight (8) year Term and the Agreement shall expire on September 10, 2023.
4.Capitalized terms not otherwise defined herein will have the meaning given them in the Agreement.
5.Incorporation and Effect of Amendment. Upon execution, this Amendment shall be made a part of the Agreement and shall be incorporated by reference. Except as specifically set forth in this Amendment, the Agreement shall remain in full force and effect without change. In the event that there is a conflict between the terms of the Agreement and this Amendment, the terms of this Amendment shall prevail.
6.Authorized
Signatories. All signatories to this Amendment represent that they are authorized by their respective companies to execute and deliver this Amendment on behalf of their respective companies, and to bind such companies to the terms herein.
7.Counterparts. This Amendment may be executed in any number of counterparts, each of which will be deemed an original but all of which together constitute a single instrument. Signatures to this Amendment transmitted by electronic mail in “portable document format” (“.pdf”) form, or by any other electronic means intended to preserve the originals graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signatures, and shall be deemed original signatures by the parties.
IN
WITNESS WHEREOF, the parties hereto have agreed to this Amendment by signing below.
